MEDI-522 + docetaxel + prednisone + zoledronic acid

This is an investigational **combination therapy** consisting of four agents: - **MEDI-522**: a humanized monoclonal IgG1 antibody targeting the αvβ3 integrin, inhibiting tumor angiogenesis by blocking the binding of ligands such as vitronectin to the integrin; developed for anti-cancer activity, particularly in metastatic solid tumors and androgen-independent prostate cancer - **Docetaxel**: a cytotoxic anti-mitotic chemotherapy agent inhibiting microtubule depolymerization, used as standard of care for prostate cancer treatment - **Prednisone**: a synthetic glucocorticoid corticosteroid exerting anti-inflammatory and immunosuppressive effects, often used to reduce inflammation and as an adjuvant to chemotherapy - **Zoledronic acid**: a bisphosphonate that inhibits osteoclast-mediated bone resorption, used to prevent skeletal-related events in patients with bone metastases This specific combination has been investigated in phase II clinical trials in patients with metastatic androgen-independent (castration-resistant) prostate cancer to evaluate anti-tumor activity and safety[1][2].